SUPN · Supernus Pharmaceuticals, Inc.
Market Cap
$2.56B
Shares
58.13M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$718.95M
+8.6%
FY2025
Net Income
-$38.55M
-152.2%
FY2025
Gross Margin
89.63%
+1.4pp
FY2025
Operating Margin
-8.66%
-21pp
FY2025
Diluted EPS
-$0.68
-151.5%
FY2025
Operating Cash Flow
$47.33M
-72.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $830.44M | $718.95M | $661.82M | $607.52M | $667.24M | $579.78M | $520.4M | $392.76M | $408.9M | $302.24M | $215M | $147.47M | $92.68M | $12.02M | $1.48M | $803K | $106K | |
| $99.03M | $74.56M | $77.91M | $83.78M | $87.22M | — | $52.46M | $16.66M | $15.36M | $15.22M | $11.99M | $8.42M | $5.76M | $1.1M | — | — | — | |
| $731.41M | $644.39M | $583.91M | $523.74M | $580.02M | — | $467.94M | $376.1M | $393.54M | $287.02M | $203.02M | $139.04M | $86.92M | $10.92M | — | — | — | |
| — | 89.63% | 88.23% | 86.21% | 86.93% | — | 89.92% | 95.76% | 96.24% | 94.97% | 94.43% | 94.29% | 93.79% | 90.81% | — | — | — | |
| $126.09M | $106.24M | $108.8M | $91.59M | $74.55M | $90.47M | $75.96M | $69.1M | $89.21M | $49.58M | $42.79M | $29.14M | $19.59M | $17.25M | $23.52M | $30.63M | $35.15M | |
| $560.88M | $485.56M | $321.58M | $336.36M | $377.22M | $304.76M | $200.68M | $153.25M | $154.7M | $137.91M | $106.01M | $89.06M | $72.61M | $55.59M | $20.13M | $7.93M | $5.08M | |
| $99.83M | $89.46M | $77.98M | $82.39M | $82.63M | $29.99M | $15.7M | $5.18M | $5.19M | $6.9M | $1.3M | $200K | $200K | $229K | $229K | $229K | $229K | |
| $97.21M | $91.56M | $80.41M | $84.86M | $85.54M | $32.6M | $18.14M | $6.66M | $7.06M | $8.13M | $2.4M | $921K | $928K | $742K | $871K | $879K | $1.19M | |
| $960.9M | $781.24M | $580.15M | $612.79M | $621.11M | $493.75M | $346.7M | $244.18M | $264.45M | $202.7M | $160.79M | $126.62M | $97.96M | $73.94M | $43.65M | $38.56M | $40.23M | |
| -$130.46M | -$62.28M | $81.67M | -$5.27M | $46.12M | $86.03M | $173.7M | $148.57M | $144.44M | $99.54M | $54.22M | $20.84M | -$5.28M | -$61.92M | -$42.17M | -$37.75M | -$40.12M | |
| — | -8.66% | 12.34% | -0.87% | 6.91% | 14.84% | 33.38% | 37.83% | 35.33% | 32.93% | 25.22% | 14.13% | -5.69% | -515.18% | -2849.26% | -4701.37% | -37851.89% | |
| -$33.25M | $29.28M | $162.08M | $79.59M | $131.67M | $118.62M | $191.84M | $155.23M | $151.51M | $107.67M | $56.62M | $21.77M | -$4.35M | -$61.18M | -$41.3M | -$36.87M | -$38.94M | |
| — | $0 | $0 | $2.42M | $7.07M | $19.7M | $19.44M | $18.21M | $13.84M | $134K | $543K | $1.23M | $4.96M | $7.85M | $3.58M | $1.87M | — | |
| — | — | — | — | — | — | — | — | $13.84M | $2.86M | $1.47M | $681K | $348K | $299K | $120K | $31K | $107K | |
| $7M | $13.25M | $16.2M | $8.04M | $14.62M | -$12.85M | -$5.05M | -$1.08M | -$4.27M | $1.08M | -$3.85M | -$6.23M | -$5.02M | -$30.35M | -$4.12M | -$1.72M | $649K | |
| -$123.47M | -$49.03M | $97.87M | $2.77M | $60.74M | $73.18M | $168.65M | $147.49M | $140.18M | $100.62M | $50.37M | $14.61M | -$10.3M | -$92.27M | -$46.28M | -$39.47M | -$39.47M | |
| -$13.58M | -$10.48M | $24.01M | $1.45M | $32K | $19.75M | $41.7M | $34.43M | $29.18M | $43.33M | -$40.85M | $666K | $630K | $0 | $0 | -$16.25M | -$399K | |
| -$109.89M | -$38.55M | $73.87M | $1.32M | $60.71M | $53.42M | $126.95M | $113.06M | $110.99M | $57.28M | $91.22M | $13.94M | -$10.93M | -$92.27M | -$46.28M | $53.82M | -$38.46M | |
| — | -5.36% | 11.16% | 0.22% | 9.1% | 9.21% | 24.39% | 28.79% | 27.14% | 18.95% | 42.43% | 9.46% | -11.79% | -767.73% | -3127.3% | 6701.74% | -36285.85% | |
| — | -$38.55M | $73.87M | $1.32M | $64.27M | $53.42M | $126.95M | $113.06M | $110.99M | $57.28M | $91.22M | $13.94M | -$10.93M | -$92.27M | -$47.43M | $50.39M | -$41.89M | |
| -$109.82M | -$38.41M | $74.27M | $3.93M | $55.96M | $45.99M | $128.51M | $123.63M | $108.58M | $56.67M | $91.58M | $13.61M | -$11.08M | -$92.22M | -$46.34M | $53.82M | -$38.47M | |
| USD/shares | -$1.92 | -$0.68 | $1.34 | $0.02 | $1.13 | $1.01 | $2.41 | $2.16 | $2.13 | $1.13 | $1.84 | $0.29 | -$0.26 | -$2.90 | -$2.72 | — | — |
| USD/shares | -$1.92 | -$0.68 | $1.32 | $0.02 | $1.04 | $0.98 | $2.36 | $2.10 | $2.05 | $1.08 | $1.76 | $0.28 | -$0.26 | -$2.90 | -$2.72 | — | — |
| shares | — | 56.45M | 55.1M | 54.54M | 53.67M | 53.1M | 52.62M | 52.41M | 51.99M | 50.76M | 49.47M | 47.49M | 42.26M | 31.85M | 17.44M | 1.61M | 1.59M |
| shares | — | 56.45M | 55.96M | 55.51M | 61.68M | 54.36M | 53.69M | 53.82M | 54.1M | 53.3M | 51.71M | 51.16M | 42.26M | 31.85M | 17.44M | 1.61M | 1.59M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.34×
EV/EBIT
—
Peer median 19.68×
P/E (TTM)
—
Peer median 16.45×
Peer medians compare against the 44 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $718,952,000 | $661,817,000 | $607,521,000 | $667,238,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $626,536,000 | $637,696,000 | $573,933,000 | — | $567,504,000 | $509,350,000 | $383,400,000 | $399,871,000 |
| Qelbree | $304,654,000 | $241,273,000 | $140,192,000 | $61,322,000 | $9,879,000 | $0 | $0 | — |
| GOCOVRI | $146,824,000 | $130,824,000 | $119,637,000 | $104,421,000 | $9,778,000 | $0 | $0 | — |
| Collaboration Revenue | $52,996,000 | $0 | $0 | — | — | — | — | — |
| APOKYN | $47,771,000 | $73,926,000 | $75,083,000 | $75,305,000 | $99,233,000 | $74,296,000 | $0 | $0 |
| Trokendi XR | $42,421,000 | $63,201,000 | $94,336,000 | $261,221,000 | $304,817,000 | $319,640,000 | $295,214,000 | $315,295,000 |
| Oxtellar XR | $40,700,000 | $99,464,000 | $113,404,000 | $115,345,000 | $110,708,000 | $98,725,000 | $88,186,000 | $84,576,000 |
| Royalty License and Other Revenue | $39,420,000 | $24,121,000 | $33,588,000 | — | — | — | — | — |
| Manufactured Product Other | $26,912,000 | $29,008,000 | $31,281,000 | $31,818,000 | $33,089,000 | $16,689,000 | — | — |
| ONAPGO | $17,254,000 | $0 | $0 | — | — | — | — | — |
| MYOBLOC | — | — | — | — | $19,514,000 | $9,746,000 | $0 | $0 |
| Osomolex ER | — | — | — | — | $188,000 | $0 | $0 | — |
| XADAGO | — | — | — | — | $13,387,000 | $6,943,000 | $0 | $0 |
| License | — | — | — | — | — | $0 | $0 | $750,000 |
| Royalty | — | — | $33,588,000 | $17,806,000 | $12,271,000 | $11,047,000 | $9,355,000 | $8,276,000 |
Key facts
CIK
1356576
CUSIP
868459108
13F (30d)
229 filings
226 filers
Visit website
Investor relations